Bokus
Benjamin Bonavida, Salem Chouaib - Hypoxia-induced Tumor Heterogeneity and Immune Evasion, Häftad

Häftad, Engelska, 2027

Hypoxia-induced Tumor Heterogeneity and Immune Evasion

Clinical Interventions

Av Benjamin Bonavida, Salem Chouaib

Del i serien Novel approaches to overcome cancer resistance to conventional therapies

2491 kr

Kommande

Beskrivning
Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. This volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. The book is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. It brings together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance. This resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.

  • Integrates hypoxia, tumor heterogeneity, and immune evasion to provide a unified framework for understanding resistance mechanisms in cancer
  • Presents cutting-edge research and clinical insights from global experts, offering a comprehensive view of tumor microenvironment dynamics
  • Equips researchers and clinicians with translational strategies to design innovative immunotherapies and improve patient outcomes
Produktinformation
Utforska kategorier
Mer om författaren

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia’s role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.

Betyg & recensioner

0 recensioner

Inga recensioner tillgängliga.